Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
20. Mai 2024 06:35 ET
|
Shah Capital
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at Novavax Still Believes Novavax Would Benefit from Stockholder...
Shah Capital nominates two highly qualified independent director candidates for Novavax
15. April 2024 06:00 ET
|
Shah Capital
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of...
Vaccine Adjuvant Market is estimated to be US$ 2.0 billion by 2032; Rising Prevalence of Infectious Diseases to Fuel the Market Growth - By PMI
25. September 2023 14:00 ET
|
PMI
Covina, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Market overview: Adjuvant is formulated as a part of vaccine to induce protection against infection in human beings. Adjuvant has become an important...
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
13. September 2023 13:34 ET
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
24. Juli 2023 08:30 ET
|
Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
10. August 2022 16:00 ET
|
Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
05. Juli 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
09. Mai 2022 08:30 ET
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
DEADLINE ALERT for SNAP, and NVAX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
10. Januar 2022 11:18 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Snap, Novavax, Zillow, and Ginkgo Bioworks and Encourages Investors to Contact the Firm
04. Januar 2022 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...